| 翻訳と辞書 |
Pasireotide
Pasireotide (SOM230, trade name Signifor〔Signifor® (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/ 〕) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease and Acromegaly in patients who fail or are ineligible for surgical therapy.〔(【引用サイトリンク】title=Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease )〕 It was developed by Novartis. Pasireotide is a somatostatin analog which has a 40-fold increased affinity to somatostatin receptor 5 than other somatostatin analogs.
The drug showed therapeutical potential in a recent study (PASPORT-CUSHINGS B2305) where 162 patients were treated with either or pasireotide s.c. daily. The effectiveness of the treatment was checked by the UFC-value (urinary free cortisol) after six months of treatment. The mean reduction of UFC after six months was 47.9%, which also lead to amelioration of clinical symptoms such as blood pressure, cholesterol value, and weight loss.
Pasireotide was approved by the EMEA in October 2009〔(EMEA Approval for Pasireotide )〕 and by the FDA in December 2012.
Pasireotide LAR was approved by the FDA for treatment of Acromegaly in December 2014. It had been approved by the EMEA a month earlier for the same use.〔Tucker, Miriam E. (FDA Approves Pasireotide for Treating Acromegaly ), ''Medscape'', December 17, 2014, Retrieved 2015-08-21〕 For Acromegaly patients, it is viewed as a more effective alternative to Octreotide, which was coming off patent.
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Pasireotide」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|